Skip to main content

Advertisement

Volume 13 Supplement 1

The evolution of anti-TNF therapy in rheumatic disease: experience, insights and advances

Reviews

Edited by Joachim Kalden

Publication of this supplement is sponsored by Merck & Company, Inc, Whitehouse Station, New Jersey, USA.

  1. Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are immune-mediated conditions that share an inflammatory mechanism fuelled by excessive cytokines, particularly TNF. Contro...

    Authors: Josef S Smolen and Paul Emery

    Citation: Arthritis Research & Therapy 2011 13(Suppl 1):S2

    Content type: Review

    Published on:

  2. Treatment strategies for rheumatoid arthritis (RA) will continue to evolve as new drugs are developed, as new data become available, and as our potential to achieve greater and more consistent outcomes becomes...

    Authors: Ferdinand C Breedveld and Bernard Combe

    Citation: Arthritis Research & Therapy 2011 13(Suppl 1):S3

    Content type: Review

    Published on:

  3. Structural changes of bone and cartilage are a hallmark of inflammatory joint diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Despite certain similaritie...

    Authors: Georg Schett, Laura C Coates, Zoe R Ash, Stefanie Finzel and Phillip G Conaghan

    Citation: Arthritis Research & Therapy 2011 13(Suppl 1):S4

    Content type: Review

    Published on:

  4. Treatment of inflammatory arthritides - including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis - has seen much progress in recent years, partially due to increased understanding of the...

    Authors: Paul P Tak and Joachim R Kalden

    Citation: Arthritis Research & Therapy 2011 13(Suppl 1):S5

    Content type: Review

    Published on:

Annual Journal Metrics

Advertisement